Clinical Trial Details

An Open-Label, Dose Escalation and Dose Expansion Trial Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of Orally Administered CA-4948 in Patients with Relapsed or Refractory Primary Central Nervous System Lymphoma

Categories (click each to see list of all clinical trials associated with that category): Lymphoma/CLL (ONC)

Current Status: Open

Phase: I (Cancer Control)

Principal Investigator: D'Angelo, Christopher

Contact Information:
Maribeth Hohenstein, RN


Part A (Dose Escalation Phase): To determine the safety and tolerability, DLTs, MTD, and RP2D of oral CA-4948 as monotherapy and in combination with ibrutinib Part B Safety of CA-4948 in combination with ibrutinib in patients with PCNSL